JP2017519727A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519727A5
JP2017519727A5 JP2016566962A JP2016566962A JP2017519727A5 JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5 JP 2016566962 A JP2016566962 A JP 2016566962A JP 2016566962 A JP2016566962 A JP 2016566962A JP 2017519727 A5 JP2017519727 A5 JP 2017519727A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
thieno
triazolo
chlorophenyl
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/060200 external-priority patent/WO2015169951A1/en
Publication of JP2017519727A publication Critical patent/JP2017519727A/ja
Publication of JP2017519727A5 publication Critical patent/JP2017519727A5/ja
Pending legal-status Critical Current

Links

JP2016566962A 2014-05-08 2015-05-08 チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 Pending JP2017519727A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461990457P 2014-05-08 2014-05-08
US61/990,457 2014-05-08
US201462012048P 2014-06-13 2014-06-13
US62/012,048 2014-06-13
US201462080751P 2014-11-17 2014-11-17
US62/080,751 2014-11-17
US201462086400P 2014-12-02 2014-12-02
US62/086,400 2014-12-02
US201562150044P 2015-04-20 2015-04-20
US62/150,044 2015-04-20
PCT/EP2015/060200 WO2015169951A1 (en) 2014-05-08 2015-05-08 Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds

Publications (2)

Publication Number Publication Date
JP2017519727A JP2017519727A (ja) 2017-07-20
JP2017519727A5 true JP2017519727A5 (cg-RX-API-DMAC7.html) 2018-06-14

Family

ID=53191652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566962A Pending JP2017519727A (ja) 2014-05-08 2015-05-08 チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法

Country Status (11)

Country Link
US (1) US9968619B2 (cg-RX-API-DMAC7.html)
EP (1) EP3139959A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017519727A (cg-RX-API-DMAC7.html)
KR (1) KR20170002610A (cg-RX-API-DMAC7.html)
CN (1) CN106852120A (cg-RX-API-DMAC7.html)
AU (1) AU2015257658A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016026046A8 (cg-RX-API-DMAC7.html)
CA (1) CA2947970A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016014574A (cg-RX-API-DMAC7.html)
RU (1) RU2016147946A (cg-RX-API-DMAC7.html)
WO (1) WO2015169951A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6243003B2 (ja) 2013-03-15 2017-12-06 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Betタンパク質阻害剤としての三環式複素環
CA2917319A1 (en) 2013-07-08 2015-01-15 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
ES2942723T3 (es) 2014-04-23 2023-06-06 Incyte Holdings Corp 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
RS64274B1 (sr) 2016-06-20 2023-07-31 Incyte Corp Kristalni čvrsti oblici bet inhibitora
EP4118431A1 (de) * 2020-03-12 2023-01-18 Heinrich-Heine-Universität Düsseldorf Inhibition von fkbp1a zur therapie des triple-negativen mammakarzinoms
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2022289869A1 (en) 2021-06-08 2023-12-21 Poseidon Innovation, Llc Anticancer compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
CA2412776C (en) 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
US8476260B2 (en) * 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012120151A1 (en) * 2011-03-10 2012-09-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Atip3 and biologically active fragments thereof for use in the treatment of cancer
JP6265979B2 (ja) 2012-06-25 2018-01-24 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法
EP2866810B9 (en) * 2012-06-27 2019-06-26 The Curators Of The University Of Missouri Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer
HK1211209A1 (en) 2012-09-28 2016-05-20 Oncoethix Gmbh Pharmaceutical formulation containing thienotriazolodiazepine compounds
DK2903616T3 (da) * 2012-10-04 2018-01-29 Ab Science Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2015018523A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa A novel bet-brd inhibitor for treatment of solid tumors

Similar Documents

Publication Publication Date Title
JP2017519727A5 (cg-RX-API-DMAC7.html)
RU2016147946A (ru) Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений
JP2017529332A5 (cg-RX-API-DMAC7.html)
RU2017100921A (ru) Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
JP2013510123A5 (cg-RX-API-DMAC7.html)
JP2012136540A5 (cg-RX-API-DMAC7.html)
RU2014124184A (ru) Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
JP2013510124A5 (cg-RX-API-DMAC7.html)
JP2016530283A5 (cg-RX-API-DMAC7.html)
JP2016529246A5 (cg-RX-API-DMAC7.html)
JP2013529611A5 (cg-RX-API-DMAC7.html)
JP2014518544A5 (cg-RX-API-DMAC7.html)
JP2018501315A5 (cg-RX-API-DMAC7.html)
RU2014105577A (ru) Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин
JP2017514907A5 (cg-RX-API-DMAC7.html)
JP2016516067A5 (cg-RX-API-DMAC7.html)
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
PH12020500327A1 (en) Macrocyclic mcl-1 inhibitors and methods of use
JP2017517579A5 (cg-RX-API-DMAC7.html)
JP2015504091A5 (cg-RX-API-DMAC7.html)
CO2017012994A2 (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
JP2019512535A5 (cg-RX-API-DMAC7.html)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
FI3865484T3 (fi) Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon